PRESS RELEASE published on 09/01/2026 at 18:00, 2 months 10 days ago THX Pharma, BBDF et Biocodex annoncent le dépôt des demandes d'autorisation de l'essai clinique de phase 3 de Batten-1 dans la maladie de Batten juvénile (CLN3) THX Pharma, accompagné de ses partenaires Beyond Batten Disease Foundation (BBDF) et Biocodex, dépose les demandes d'autorisation réglementaire pour l'essai clinique de phase 3 de Batten-1, un traitement pour la maladie de Batten juvénile (CLN3) Essai Clinique Maladie De Batten THX Pharma Biocodex Beyond Batten Disease Foundation
BRIEF published on 07/09/2026 at 18:05, 4 months 2 days ago THX Pharma maintains its financial stability as of June 30, 2026 Treasury Phase 3 TX01 THX Pharma Biocodex
BRIEF published on 07/09/2026 at 18:05, 4 months 2 days ago THX Pharma maintient sa stabilité financière au 30 juin 2026 Trésorerie Phase 3 TX01 THX Pharma Biocodex
BRIEF published on 07/09/2026 at 18:05, 4 months 2 days ago THX Pharma Announces June 2026 Cash Position Cash Position Phase 3 Study Batten Disease Niemann-Pick Disease THX Pharma
BRIEF published on 07/09/2026 at 18:05, 4 months 2 days ago THX Pharma annonce sa trésorerie en juin 2026. Étude De Phase 3 Maladie De Batten Maladie De Niemann-Pick THX Pharma Position De Trésorerie
PRESS RELEASE published on 07/09/2026 at 18:00, 4 months 2 days ago THX Pharma publie sa position de trésorerie au 30 juin 2026 THX Pharma annonce sa trésorerie au 30 juin 2026 et les avancées majeures du premier semestre. Position financière solide pour la phase 3 de la maladie de Batten Trésorerie Position Financière Batten-1 Maladies Neurologiques Rares THX Pharma
PRESS RELEASE published on 07/09/2026 at 18:00, 4 months 2 days ago THX Pharma Reports Cash Position as of June 30, 2026 THX Pharma (Theranexus) announces cash position of €17.5 million as of June 30, 2026. Biocodex funds clinical development costs for Batten-1 program. Positive milestones achieved in 2026 towards commercialization Cash Position Commercialization THX Pharma Biocodex Batten-1 Program
BRIEF published on 06/23/2026 at 18:05, 4 months 18 days ago THX Pharma nomme Sophie Jacq Lapointe à son conseil d'administration Conseil D'administration Maladies Rares Stratégie Pharmaceutique THX Pharma Sophie Jacq Lapointe
BRIEF published on 06/23/2026 at 18:05, 4 months 18 days ago THX Pharma Accueille Sophie Jacq Lapointe dans son Conseil d'administration Conseil D'administration Stratégie Pharmaceutique THX Pharma Commercialisation Internationale Sophie Jacq Lapointe
BRIEF published on 06/23/2026 at 18:05, 4 months 18 days ago THX Pharma Appoints Sophie Jacq Lapointe to Board of Directors Board Of Directors Rare Diseases Pharmaceutical Strategy THX Pharma Sophie Jacq Lapointe
Published on 11/11/2026 at 19:31, 3 hours 4 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 6 hours 5 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 8 hours 10 minutes ago Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 8 hours 35 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 8 hours 35 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 3 hours 6 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 3 hours 53 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 4 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 4 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 5 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 5 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
